President and General Manager
With nearly 25 years of global experience in pharmaceutical management, Patrick Cashman oversees the Canadian research and commercial operations for Lundbeck’s Canadian subsidiary. Lundbeck is a Danish leading pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases and cancer.
Mr. Cashman joined Lundbeck in 1998 and established the company’s operations in Mexico, becoming the Regional Vice President for Latin America. In 2005, he was named President of Lundbeck USA, where he expanded the company’s activities in the American market.
Since Patrick Cashman became the President of Lundbeck Canada in 2007, sales nearly doubled. In 2010 and 2011, Lundbeck Canada was among the 50 fastest growing Canadian pharmaceutical companies. Mr. Cashman also contributed to the development of a successful oncology business unit in Canada, the first with Lundbeck globally.
Mr. Cashman believes in the importance of creating working conditions that foster employee mobilization and engagement. For the past three years, Lundbeck Canada has been recognized among the top 20 employers in Montreal, where the head office is based.
Prior to joining Lundbeck in 1998, Mr. Cashman performed management roles in companies including Monsanto, Pfizer, and Smithkline Beecham.
Mr. Cashman holds a Masters of Business Administration Degree with Honours from Thunderbird School of International Business as well as a Bachelor’s degree in Economics from the University of Wisconsin-Madison. In 2014, he received the “Eyeforpharma” International Lifetime Achievement Award for recognizing the needs of patients and their families living with mental illness and for always putting the patient first.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.